Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Combined Photosensitization and Vaccination Enable CD8 T-Cell Immunity and Tumor Suppression Independent of CD4 T-Cell Help.

Varypataki EM, Hasler F, Waeckerle-Men Y, Vogel-Kindgen S, Høgset A, Kündig TM, Gander B, Halin C, Johansen P.

Front Immunol. 2019 Jul 5;10:1548. doi: 10.3389/fimmu.2019.01548. eCollection 2019.

2.

Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine.

Mohsen MO, Vogel M, Riether C, Muller J, Salatino S, Ternette N, Gomes AC, Cabral-Miranda G, El-Turabi A, Ruedl C, Kundig TM, Dermime S, Knuth A, Speiser DE, Bachmann MF.

Front Immunol. 2019 May 15;10:1015. doi: 10.3389/fimmu.2019.01015. eCollection 2019.

3.

Correction to: Vaccination with nanoparticles combined with micro-adjuvants protects against cancer.

Mohsen MO, Heath MD, Cabral-Miranda G, Lipp C, Zeltins A, Sande M, Stein JV, Riether C, Roesti E, Zha L, Engeroff P, El-Turabi A, Kundig TM, Vogel M, Skinner MA, Speiser DE, Knuth A, Kramer MF, Bachmann MF.

J Immunother Cancer. 2019 May 23;7(1):137. doi: 10.1186/s40425-019-0616-y.

4.

Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects.

Thoms F, Jennings GT, Maudrich M, Vogel M, Haas S, Zeltins A, Hofmann-Lehmann R, Riond B, Grossmann J, Hunziker P, Fettelschoss-Gabriel A, Senti G, Kündig TM, Bachmann MF.

J Allergy Clin Immunol. 2019 Jul;144(1):193-203. doi: 10.1016/j.jaci.2019.01.050. Epub 2019 May 2.

5.

Vaccination with nanoparticles combined with micro-adjuvants protects against cancer.

Mohsen MO, Heath MD, Cabral-Miranda G, Lipp C, Zeltins A, Sande M, Stein JV, Riether C, Roesti E, Zha L, Engeroff P, El-Turabi A, Kundig TM, Vogel M, Skinner MA, Speiser DE, Knuth A, Kramer MF, Bachmann MF.

J Immunother Cancer. 2019 Apr 26;7(1):114. doi: 10.1186/s40425-019-0587-z. Erratum in: J Immunother Cancer. 2019 May 23;7(1):137.

6.

Letter to the Editor: Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.

Wüthrich B, Senti G, Kündig TM.

J Eur Acad Dermatol Venereol. 2019 Apr;33(4):e151-e153. doi: 10.1111/jdv.15382. Epub 2019 Jan 15. No abstract available.

PMID:
30520147
7.

Active vaccination against interleukin-5 as long-term treatment for insect-bite hypersensitivity in horses.

Fettelschoss-Gabriel A, Fettelschoss V, Olomski F, Birkmann K, Thoms F, Bühler M, Kummer M, Zeltins A, Kündig TM, Bachmann MF.

Allergy. 2019 Mar;74(3):572-582. doi: 10.1111/all.13659. Epub 2018 Nov 25.

8.

Intralymphatic Immunotherapy: Update and Unmet Needs.

Senti G, Freiburghaus AU, Larenas-Linnemann D, Hoffmann HJ, Patterson AM, Klimek L, Di Bona D, Pfaar O, Ahlbeck L, Akdis M, Weinfeld D, Contreras-Verduzco FA, Pedroza-Melendez A, Skaarup SH, Lee SM, Cardell LO, Schmid JM, Westin U, Dollner R, Kündig TM.

Int Arch Allergy Immunol. 2019;178(2):141-149. doi: 10.1159/000493647. Epub 2018 Nov 2. Review.

9.

Treating insect-bite hypersensitivity in horses with active vaccination against IL-5.

Fettelschoss-Gabriel A, Fettelschoss V, Thoms F, Giese C, Daniel M, Olomski F, Kamarachev J, Birkmann K, Bühler M, Kummer M, Zeltins A, Marti E, Kündig TM, Bachmann MF.

J Allergy Clin Immunol. 2018 Oct;142(4):1194-1205.e3. doi: 10.1016/j.jaci.2018.01.041. Epub 2018 Apr 4.

10.

Microcrystalline Tyrosine and Aluminum as Adjuvants in Allergen-Specific Immunotherapy Protect from IgE-Mediated Reactivity in Mouse Models and Act Independently of Inflammasome and TLR Signaling.

Leuthard DS, Duda A, Freiberger SN, Weiss S, Dommann I, Fenini G, Contassot E, Kramer MF, Skinner MA, Kündig TM, Heath MD, Johansen P.

J Immunol. 2018 May 1;200(9):3151-3159. doi: 10.4049/jimmunol.1800035. Epub 2018 Mar 28.

11.

PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer.

Spalinger MR, Manzini R, Hering L, Riggs JB, Gottier C, Lang S, Atrott K, Fettelschoss A, Olomski F, Kündig TM, Fried M, McCole DF, Rogler G, Scharl M.

Cell Rep. 2018 Feb 13;22(7):1835-1848. doi: 10.1016/j.celrep.2018.01.052.

12.

Oxidative stress and altered mitochondrial protein expression in the absence of amyloid-β and tau pathology in iPSC-derived neurons from sporadic Alzheimer's disease patients.

Birnbaum JH, Wanner D, Gietl AF, Saake A, Kündig TM, Hock C, Nitsch RM, Tackenberg C.

Stem Cell Res. 2018 Mar;27:121-130. doi: 10.1016/j.scr.2018.01.019. Epub 2018 Jan 28.

13.

Intraperitoneal administration of aluminium-based adjuvants produces severe transient systemic adverse events in mice.

Freiberger SN, Leuthard DS, Duda A, Contassot E, Thallmair M, Kündig TM, Johansen P.

Eur J Pharm Sci. 2018 Mar 30;115:362-368. doi: 10.1016/j.ejps.2018.01.042. Epub 2018 Feb 2.

PMID:
29410031
14.

Pillars Article: Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function. Science. 1997. 275: 540-543.

Mittrücker HW, Matsuyama T, Grossman A, Kündig TM, Potter J, Shahinian A, Wakeham A, Patterson B, Ohashi PS, Mak TW.

J Immunol. 2017 Dec 1;199(11):3717-3720. No abstract available.

15.

Cutaneous Corynebacterium Infection Presenting with Disseminated Skin Nodules and Ulceration.

Kolios AGA, Cozzio A, Zinkernagel AS, French LE, Kündig TM.

Case Rep Dermatol. 2017 May 16;9(2):8-12. doi: 10.1159/000476054. eCollection 2017 May-Aug.

16.

Distinct T helper cell dependence of memory B-cell proliferation versus plasma cell differentiation.

Zabel F, Fettelschoss A, Vogel M, Johansen P, Kündig TM, Bachmann MF.

Immunology. 2017 Mar;150(3):329-342. doi: 10.1111/imm.12688. Epub 2017 Jan 5.

17.

Allergen-specific immunotherapy: is it vaccination against toxins after all?

Bachmann MF, Kündig TM.

Allergy. 2017 Jan;72(1):13-23. doi: 10.1111/all.12890. Epub 2016 Sep 28. Review.

PMID:
27558586
18.

IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant MAT-Feld1 in human.

Freiberger SN, Zehnder M, Gafvelin G, Grönlund H, Kündig TM, Johansen P.

Allergy. 2016 Sep;71(9):1366-70. doi: 10.1111/all.12946. Epub 2016 Jun 17.

PMID:
27253988
19.

Novel Delivery Routes for Allergy Immunotherapy: Intralymphatic, Epicutaneous, and Intradermal.

Senti G, Kündig TM.

Immunol Allergy Clin North Am. 2016 Feb;36(1):25-37. doi: 10.1016/j.iac.2015.08.006. Review.

PMID:
26617225
20.

Dosing intervals in intralymphatic immunotherapy.

Hjálmsdóttir Á, Wäckerle-Men Y, Duda A, Kündig TM, Johansen P.

Clin Exp Allergy. 2016 Mar;46(3):504-7. doi: 10.1111/cea.12657. No abstract available.

PMID:
26470052
21.

Comparison of microneedles and adhesive-tape stripping in skin preparation for epicutaneous allergen delivery.

Spina L, Weisskopf M, von Moos S, Graf N, Kündig TM, Senti G.

Int Arch Allergy Immunol. 2015;167(2):103-9. doi: 10.1159/000434681. Epub 2015 Aug 12.

22.

A bizarre attack on the freedom of scientific expression.

Senti G, Johansen P, von Moos S, Kündig TM.

Allergy. 2015 Sep;70(9):1037-8. doi: 10.1111/all.12660. No abstract available.

PMID:
26032463
23.

Photosensitizer and Light Pave the Way for Cytosolic Targeting and Generation of Cytosolic CD8 T Cells Using PLGA Vaccine Particles.

Bruno C, Waeckerle-Men Y, Håkerud M, Kündig TM, Gander B, Johansen P.

J Immunol. 2015 Jul 1;195(1):166-73. doi: 10.4049/jimmunol.1500431. Epub 2015 May 27.

24.

Intralymphatic immunotherapy.

Senti G, Kündig TM.

World Allergy Organ J. 2015 Mar 7;8(1):9. doi: 10.1186/s40413-014-0047-7. eCollection 2015.

25.

Is The Allergen Really Needed in Allergy Immunotherapy?

Kündig TM, Klimek L, Schendzielorz P, Renner WA, Senti G, Bachmann MF.

Curr Treat Options Allergy. 2015;2(1):72-82. Review.

26.

Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials.

Senti G, von Moos S, Tay F, Graf N, Johansen P, Kündig TM.

Allergy. 2015 Jun;70(6):707-10. doi: 10.1111/all.12600. Epub 2015 Mar 13.

27.

Photosensitisation facilitates cross-priming of adjuvant-free protein vaccines and stimulation of tumour-suppressing CD8 T cells.

Håkerud M, Selbo PK, Waeckerle-Men Y, Contassot E, Dziunycz P, Kündig TM, Høgset A, Johansen P.

J Control Release. 2015 Jan 28;198:10-7. doi: 10.1016/j.jconrel.2014.11.032. Epub 2014 Dec 4.

PMID:
25482339
28.

[Transcutaneous applications for vaccination and immunotherapy].

Krämer I, Zabel F, Kündig TM, Johansen P.

Praxis (Bern 1994). 2014 Oct 15;103(21):1247-55. doi: 10.1024/1661-8157/a001802. Review. German.

PMID:
25305116
29.

Comparing safety of abrasion and tape-stripping as skin preparation in allergen-specific epicutaneous immunotherapy.

von Moos S, Johansen P, Tay F, Graf N, Kündig TM, Senti G.

J Allergy Clin Immunol. 2014 Oct;134(4):965-7.e4. doi: 10.1016/j.jaci.2014.07.037. No abstract available.

30.

Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine.

Zaleska A, Eiwegger T, Soyer O, van de Veen W, Rhyner C, Soyka MB, Bekpen C, Demiröz D, Treis A, Söllner S, Palomares O, Kwok WW, Rose H, Senti G, Kündig TM, Ozoren N, Jutel M, Akdis CA, Crameri R, Akdis M.

Allergy. 2014 Sep;69(9):1162-70. doi: 10.1111/all.12461. Epub 2014 Jul 12. Erratum in: Allergy. 2016 Jan;71(1):129.

PMID:
24934402
31.

A critical appraisal of analyzing nasal provocation test results in allergen immunotherapy trials.

Graf N, Dinkel B, Rose H, Hothorn LA, Gerhard D, Johansen P, Kundig TM, Klimek L, Senti G.

Rhinology. 2014 Jun;52(2):137-41. doi: 10.4193/Rhin13.145.

PMID:
24932625
32.

Epicutaneous Immunotherapy for Aeroallergen and Food Allergy.

Senti G, von Moos S, Kündig TM.

Curr Treat Options Allergy. 2013 Dec 17;1:68-78. eCollection 2014. Review.

33.

Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs.

Klimek L, Bachmann MF, Senti G, Kündig TM.

Expert Rev Clin Immunol. 2014 Aug;10(8):1059-67. doi: 10.1586/1744666X.2014.924854. Epub 2014 Jun 5. Review.

PMID:
24898577
34.

Viral particles drive rapid differentiation of memory B cells into secondary plasma cells producing increased levels of antibodies.

Zabel F, Mohanan D, Bessa J, Link A, Fettelschoss A, Saudan P, Kündig TM, Bachmann MF.

J Immunol. 2014 Jun 15;192(12):5499-508. doi: 10.4049/jimmunol.1400065. Epub 2014 May 12.

35.

Intralymphatic immunotherapy and vaccination in mice.

Johansen P, Kündig TM.

J Vis Exp. 2014 Feb 2;(84):e51031. doi: 10.3791/51031.

36.

Intralymphatic immunotherapy: time interval between injections is essential.

Kündig TM, Johansen P, Bachmann MF, Cardell LO, Senti G.

J Allergy Clin Immunol. 2014 Mar;133(3):930-1. doi: 10.1016/j.jaci.2013.11.036. Epub 2014 Jan 15. No abstract available.

PMID:
24439076
37.

IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization.

Uermösi C, Zabel F, Manolova V, Bauer M, Beerli RR, Senti G, Kündig TM, Saudan P, Bachmann MF.

Allergy. 2014 Mar;69(3):338-47. doi: 10.1111/all.12327. Epub 2013 Dec 19. Erratum in: Allergy. 2014 Aug;69(8):1118.

PMID:
24354793
38.

Multivalent paediatric allergy vaccines protect against allergic anaphylaxis in mice.

Waeckerle-Men Y, Liang Y, von Moos S, Kündig TM, Johansen P.

Clin Exp Allergy. 2014 Mar;44(3):429-37. doi: 10.1111/cea.12245.

PMID:
24286478
39.

Intradermal photosensitisation facilitates stimulation of MHC class-I restricted CD8 T-cell responses of co-administered antigen.

Håkerud M, Waeckerle-Men Y, Selbo PK, Kündig TM, Høgset A, Johansen P.

J Control Release. 2014 Jan 28;174:143-50. doi: 10.1016/j.jconrel.2013.11.017. Epub 2013 Nov 23.

PMID:
24280261
40.

[Immunotherapy of allergic rhinitis without allergens? : new options for immunomodulation by vaccination with virus-like particles and CpG motifs].

Klimek L, Willers J, Schendzielorz P, Kündig TM, Senti G.

HNO. 2013 Oct;61(10):826-33. doi: 10.1007/s00106-013-2761-9. German.

PMID:
24127047
41.

Virus-induced humoral immunity: on how B cell responses are initiated.

Zabel F, Kündig TM, Bachmann MF.

Curr Opin Virol. 2013 Jun;3(3):357-62. doi: 10.1016/j.coviro.2013.05.004. Epub 2013 Jun 1. Review.

PMID:
23731601
42.

Photochemical targeting of antigens to the cytosol for stimulation of MHC class-I-restricted T-cell responses.

Waeckerle-Men Y, Mauracher A, Håkerud M, Mohanan D, Kündig TM, Høgset A, Johansen P.

Eur J Pharm Biopharm. 2013 Sep;85(1):34-41. doi: 10.1016/j.ejpb.2013.02.002. Epub 2013 Feb 24.

PMID:
23461859
43.

The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines.

Döbbeling U, Waeckerle-Men Y, Zabel F, Graf N, Kündig TM, Johansen P.

Exp Dermatol. 2013 Feb;22(2):119-24. doi: 10.1111/exd.12086.

PMID:
23362870
44.

Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis.

Waeckerle-Men Y, Bruffaerts N, Liang Y, Jurion F, Sander P, Kündig TM, Huygen K, Johansen P.

Vaccine. 2013 Feb 4;31(7):1057-64. doi: 10.1016/j.vaccine.2012.12.034. Epub 2012 Dec 25.

PMID:
23273509
45.

A VLP-based vaccine against interleukin-1α protects mice from atherosclerosis.

Tissot AC, Spohn G, Jennings GT, Shamshiev A, Kurrer MO, Windak R, Meier M, Viesti M, Hersberger M, Kündig TM, Ricci R, Bachmann MF.

Eur J Immunol. 2013 Mar;43(3):716-22. doi: 10.1002/eji.201242687. Epub 2013 Jan 28.

46.

Stroma-derived interleukin-34 controls the development and maintenance of langerhans cells and the maintenance of microglia.

Greter M, Lelios I, Pelczar P, Hoeffel G, Price J, Leboeuf M, Kündig TM, Frei K, Ginhoux F, Merad M, Becher B.

Immunity. 2012 Dec 14;37(6):1050-1060. doi: 10.1016/j.immuni.2012.11.001. Epub 2012 Nov 21.

47.

Low-affinity B cells transport viral particles from the lung to the spleen to initiate antibody responses.

Bessa J, Zabel F, Link A, Jegerlehner A, Hinton HJ, Schmitz N, Bauer M, Kündig TM, Saudan P, Bachmann MF.

Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20566-71. doi: 10.1073/pnas.1206970109. Epub 2012 Nov 20.

48.

TLR4- and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell-independent isotype switch in mice.

Pihlgren M, Silva AB, Madani R, Giriens V, Waeckerle-Men Y, Fettelschoss A, Hickman DT, López-Deber MP, Ndao DM, Vukicevic M, Buccarello AL, Gafner V, Chuard N, Reis P, Piorkowska K, Pfeifer A, Kündig TM, Muhs A, Johansen P.

Blood. 2013 Jan 3;121(1):85-94. doi: 10.1182/blood-2012-02-413831. Epub 2012 Nov 8.

49.

New routes for allergen immunotherapy.

Johansen P, von Moos S, Mohanan D, Kündig TM, Senti G.

Hum Vaccin Immunother. 2012 Oct;8(10):1525-33. doi: 10.4161/hv.21948. Epub 2012 Oct 1. Review.

50.

Risk assessment of Hymenoptera re-sting frequency: implications for decision-making in venom immunotherapy.

von Moos S, Graf N, Johansen P, Müllner G, Kündig TM, Senti G.

Int Arch Allergy Immunol. 2013;160(1):86-92. doi: 10.1159/000338942. Epub 2012 Sep 1.

Supplemental Content

Loading ...
Support Center